LILRB1 Antibody (Center) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q8NHL6 |
---|---|
Clone Names | 100617270 |
Gene ID | 10859 |
---|---|
Other Names | Leukocyte immunoglobulin-like receptor subfamily B member 1, LIR-1, Leukocyte immunoglobulin-like receptor 1, CD85 antigen-like family member J, Immunoglobulin-like transcript 2, ILT-2, Monocyte/macrophage immunoglobulin-like receptor 7, MIR-7, CD85j, LILRB1, ILT2, LIR1, MIR7 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | LILRB1 {ECO:0000303|PubMed:20600445, ECO:0000312|HGNC:HGNC:6605} |
---|---|
Function | Receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles (PubMed:16455647, PubMed:28636952). Receptor for H301/UL18, a human cytomegalovirus class I MHC homolog. Ligand binding results in inhibitory signals and down-regulation of the immune response. Engagement of LILRB1 present on natural killer cells or T-cells by class I MHC molecules protects the target cells from lysis. Interaction with HLA-B or HLA-E leads to inhibition of FCER1A signaling and serotonin release. Inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions (PubMed:11907092, PubMed:9285411, PubMed:9842885). Recognizes HLA-G in complex with B2M/beta-2 microglobulin and a nonamer self-peptide (PubMed:16455647). Upon interaction with peptide-bound HLA-G-B2M complex, triggers secretion of growth-promoting factors by decidual NK cells (PubMed:29262349, PubMed:19304799). Reprograms B cells toward an immune suppressive phenotype (PubMed:24453251). |
Cellular Location | Cell membrane; Single-pass type I membrane protein |
Tissue Location | Expressed in B cells, monocytes and various dendritic cell (DC) subsets including myeloid, plasmacytoid and tolerogenic DCs (at protein level) (PubMed:20448110, PubMed:9285411, PubMed:9842885, PubMed:24453251). Expressed in decidual macrophages (at protein level) (PubMed:19304799). Expressed in decidual NK cells (at protein level) (PubMed:29262349). |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene is a member of the leukocyte immunoglobulin-likereceptor (LIR) family, which is found in a gene cluster atchromosomal region 19q13.4. The encoded protein belongs to thesubfamily B class of LIR receptors which contain two or fourextracellular immunoglobulin domains, a transmembrane domain, andtwo to four cytoplasmic immunoreceptor tyrosine-based inhibitorymotifs (ITIMs). The receptor is expressed on immune cells where itbinds to MHC class I molecules on antigen-presenting cells andtransduces a negative signal that inhibits stimulation of an immuneresponse. It is thought to control inflammatory responses andcytotoxicity to help focus the immune response and limitautoreactivity. Multiple transcript variants encoding differentisoforms have been found for this gene.
References
Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)Davidson, C.L., et al. Hum. Immunol. 71(10):942-949(2010)Huang, J., et al. J. Virol. 84(18):9463-9471(2010)Godal, R., et al. Biol. Blood Marrow Transplant. 16(5):612-621(2010)Lamar, D.L., et al. Blood 115(16):3278-3286(2010)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.